Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05205967 · ClinicalTrials.gov registry record
REFLECTION: A Clinical Practice Learning Program for Galleri®
A clinical trial of Cancer and Early Detection of Cancer, sponsored by GRAIL.
- Active
- Registry status
- 14,633
- Enrollment target
- 16
- Study locations
NCT05205967 is a study of Cancer and Early Detection of Cancer that is active but no longer recruiting, run by GRAIL. The registered enrollment target is 14,633 participants, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (322% higher). The trial reports 16 study locations across 10 states.
The verdict
NCT05205967, a study of Cancer and Early Detection of Cancer, is active but no longer recruiting, sponsored by GRAIL.
- ACTIVE NOT RECRUITING
- Registry status
- 14,633 participants
- Enrollment target
- 16
- Study locations
Study Summary
REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand the real-world experience of Galleri® in clinical settings.
Conditions Studied
Interventions
- OTHER SOC
- OTHER MCED
Study Locations (16)
California
- Providence - Burbank
- Providence, St. Jude - Fullerton
- Providence, Mission - Mission Viejo
- Providence, Orange County - Orange
Florida
- VA Miami Health Care System - Miami
- James A. Haley Veterans Hospital (VA Tampa) - Tampa
Pennsylvania
- VA Pittsburgh Healthcare System - Pittsburgh
- VA Wilkes Barre Medical Center - Wilkes-Barre
South Carolina
- Carolina Blood and Cancer Care Associate - Lancaster
- Carolina Blood and Cancer Care Associates - Rock Hill
Arizona
- Vincere Cancer Center - Scottsdale
Louisiana
- Southeast Louisiana Veterans Health Care System (SLVHCS) (VA New Orleans) - New Orleans
Massachusetts
- Boston VA Research Institute (VA Boston) - Boston
Oregon
- Providence - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14,633 participants |
| Start Date | 2021-08-23 |
| Est. Completion | 2026-10-30 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05205967
The ClinicalTrials.gov registry entry for NCT05205967 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 14,633 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 3,467-participant average among 615 other Cancer trials with a reported enrollment target (322% higher). The listed sponsor is GRAIL, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Cancer appearing as the primary indexed condition, and to 2 interventions - of which SOC is the first listed.
NCT05205967 reports 16 study locations spanning 10 distinct geographic areas - top geographies include California, Florida, Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT05205967 about?
NCT05205967 is a clinical study titled "REFLECTION: A Clinical Practice Learning Program for Galleri®". REFLECTION is a multi-center, prospective, non-interventional, cohort study that will enroll approximately 14,000 individuals who have opted to be screened with Galleri®, a blood-based, multi-cancer early detection (MCED) test in routine clinical settings. The purpose of the study is to understand t...
What is the current status of trial NCT05205967?
This trial is currently active not recruiting. The enrollment target is 14,633 participants. The study started on 2021-08-23. Estimated completion is 2026-10-30.
What conditions does trial NCT05205967 study?
This clinical trial studies the following conditions: Cancer, Early Detection of Cancer.
What interventions are being tested in trial NCT05205967?
The interventions under investigation include: SOC (OTHER), MCED (OTHER).
Who is sponsoring clinical trial NCT05205967?
This trial is sponsored by GRAIL, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05205967 being conducted?
This trial has 16 study locations across Arizona, California, Florida, Louisiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Registry Study to Evaluate the Clinical Outcome of Cancer Patients and Benign Diseases Treated with Radiation
RECRUITING
-
Treatment of Immune Checkpoint Inhibitor-related Diarrhea and/ or Colitis With Ustekinumab in Cancer Patients
RECRUITING · Phase 2
-
IMPACT (IMproving Proactive Approaches for Cancer Survivors' Mental Health Treatment)
RECRUITING · NA
-
A Natural History Study of Metabolic Sizing in Health and Disease
RECRUITING
-
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
RECRUITING · Phase 1
-
Long-Term Follow-Up of Recipient of Gene Transfer Research
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.